Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Phase I Study of the Safety, Tolerability and Pharmacokinetics of a Single Intravenous Dose of ETI-204 (Anthim) [Elusys Protocol Number AH-102].
Phase of Trial: Phase I
Latest Information Update: 14 Sep 2016
At a glance
- Drugs Obiltoxaximab (Primary)
- Indications Anthrax
- Focus Adverse reactions
- Sponsors EluSys Therapeutics
- 14 Sep 2016 According to an Elusys Therapeutics media release, results from this study are published online at Clinical Therapeutics.
- 24 Aug 2016 Results assessing safety, immunogenicity, and pharmacokinetics of this and other four studies published in the Clinical Therapeutics
- 21 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.